序贯吉西他滨联合多西他赛是卡介苗无反应性非肌层浸润性膀胱癌的标准二线膀胱内治疗方法：专家观点
Sequential Gemcitabine plus Docetaxel Is the Standard Second-line Intravesical Therapy for BCG-unresponsive Non-muscle-invasive bladder cancer: Pro.
作者信息
Roumiguié Mathieu, Black Peter C
机构信息
Department of Urology, CHU Institut Universitaire du Cancer de Toulouse, Toulouse, France; Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, Canada.
Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, Canada.
出版信息
Eur Urol Focus. 2022 Jul;8(4):1117-1120. doi: 10.1016/j.euf.2021.07.018. Epub 2021 Sep 27.
Docetaxel and gemcitabine have different mechanisms of action, are well tolerated as monotherapies, and are affordable. This combination represents a good option for the second-line, bladder-preserving standard of care for non-muscle-invasive bladder cancer unresponsive to bacillus Calmette-Guérin.
多西他赛和吉西他滨作用机制不同，单药治疗耐受性良好且价格可承受。对于对卡介苗无反应的非肌层浸润性膀胱癌，这种联合用药方案是二线膀胱保留标准治疗的一个不错选择。
Zotero 插件